IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook
IDXX•IDEXX Laboratories’ third-quarter revenue rose 10% to $1.21 billion, beating the $1.19 billion estimate, while EPS increased 18% to $4.01. The company raised its 2026 revenue and EPS outlook but lowered its operating margin outlook.
1. Quarterly results
IDEXX Laboratories reported third-quarter revenue of $1.21 billion, up 10% and above the $1.19 billion analyst estimate. EPS rose 18% to $4.01; gross margin was 62.9% and EBIT margin was 33.1%.
2. 2026 outlook
The company raised its 2026 revenue outlook to $4.74 billion-$4.77 billion, an increase of $32 million at the midpoint, and raised its EPS guidance to $14.96-$15.16, up $0.25 from the prior midpoint. It lowered its operating margin outlook to 32.1%-32.3% from 32.3%-32.5%.
3. Revenue drivers
Recurring revenue growth was driven by same-store volume, customer gains and an expanded instrument base. New analyzers and expanded diagnostic panels also contributed to revenue growth, while net price gains and operational productivity supported margin expansion.
